Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases
Pivotal Phase 3 Clinical Study
Our lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
We focus on rare respiratory diseases in order to give patients with unmet medical needs better treatment options.
Savara Nasdaq Opening Bell Ceremony - July 23, 2018×